Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Mar-Apr:40:101981.
doi: 10.1016/j.tmaid.2021.101981. Epub 2021 Jan 31.

Risk of Strongyloides Hyperinfection Syndrome when prescribing dexamethasone in severe COVID-19

Angus De Wilton  1 , Laura E Nabarro  2 , Gauri S Godbole  3 , Peter L Chiodini  4 , Aileen Boyd  5 , Katherine Woods  6
Affiliations
Comment

Risk of Strongyloides Hyperinfection Syndrome when prescribing dexamethasone in severe COVID-19

Angus De Wilton et al. Travel Med Infect Dis. 2021 Mar-Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests to declare.

Figures

Fig. 1
Fig. 1
Risk Assessment and Screening Algorithm.
See this image and copyright information in PMC

Comment on

References

    1. Patel S.K., Saikumar G., Rana J., Dhama J., Yatoo M.I., Tiwari R., Rodríguez-Morales A.J., Dhama K. Dexamethasone: a boon for critically ill COVID-19 patients? Trav Med Infect Dis. 2020 Sep-Oct;37:101844. doi: 10.1016/j.tmaid.2020.101844. - DOI - PMC - PubMed
    1. Lier A.J., Tuan J.J., Davis M.W., Paulson N., McManus D., Campbell S., Peaper D.R., Topal J.E. Case report: disseminated strongyloidiasis in a patient with COVID-19. Am J Trop Med Hyg. 2020 Oct;103(4):1590–1592. doi: 10.4269/ajtmh.20-0699. - DOI - PMC - PubMed
    1. Marchese V., Crosato V., Gulletta M., Castelnuovo F., Cristini G., Matteelli A., Castelli F. Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia. Infection. 2020 Sep 10:1–4. doi: 10.1007/s15010-020-01522-4. - DOI - PMC - PubMed
    1. Ming D.K., Armstrong M., Lowe P., Chiodini P.L., Doherty J.F., Whitty C.J.M., McGregor A.C. Clinical and diagnostic features of 413 patients treated for imported strongyloidiasis at the hospital for tropical Diseases, London. Am J Trop Med Hyg. 2019 Aug;101(2):428–431. doi: 10.4269/ajtmh.19-0087. - DOI - PMC - PubMed
    1. Buonfrate D., Salas-Coronas J., Muñoz J., Maruri B.T., Rodari P., Castelli F., Zammarchi L., Bianchi L., Gobbi F., Cabezas-Fernández T., Requena-Mendez A., Godbole G., Silva R., Romero M., Chiodini P.L., Bisoffi Z. Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial. Lancet Infect Dis. 2019 Nov;19(11):1181–1190. doi: 10.1016/S1473-3099(19)30289-0. Epub 2019 Sep. 23. - DOI - PubMed

LinkOut - more resources